Lumeon wins MedTech Breakthrough Award - Gilde Healthcare

Lumeon wins MedTech Breakthrough Award

June 7, 2017

LONDON AND NEW YORK – Lumeon, a leading digital health company, has won the MedTech Breakthrough Award for Best Overall Health Administration Software. The awards recognize the top companies, people, platforms and products in the global health and medical technology market today.

Lumeon’s Care Pathway Management (CPM) platform, that allows providers to automate and orchestrate workflows across the care continuum, impressed the judges with its capability to digitize risk reducing strategies, improve efficiency and scale best practice.

Robbie Hughes, Lumeon’s CEO said, “Alternative payment models are prompting the industry to think differently about the way care is delivered and how we collaboratively manage risk to deliver better quality outcomes. Providers want better visibility into outcomes data across the care continuum, as well as innovative ways of engaging patients and managing healthcare administration. I’m delighted to accept this award as we continue to deliver solutions that are both personalized and scalable.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories. This year’s program attracted more than 2,000 nominations from over 10 different countries throughout the world. All nominations were evaluated by an independent panel of experts within the medical and health industry.

“We are pleased to recognize Lumeon among the MedTech Breakthrough Awards this year,” stated James Johnson, Managing Director at MedTech Breakthrough. “Health administration can be an extremely complex proposition for healthcare providers, taking focus away from the ultimate goal of improving patient care. By automating and simplifying health workflows with software such as Lumeon’s Care Pathway Management platform, we see tremendous benefits for healthcare providers and patients alike. Congratulations to the entire Lumeon team on their industry recognition.”

More news

Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease

First dose-expansion patient successfully received SB-007  SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations  SB-007 granted FDA Fast Track designation, following previously received Orphan Drug...
January 9, 2026

Gilde Healthcare acquires a majority stake in Physio CKI, a physiotherapy practice group, from Kapital 1852

Gilde Healthcare's private equity fund announces the acquisition of a majority stake in Physio CKI from Kapital 1852. Physio CKI is a fast-growing group of physiotherapy practices headquartered in Cologne. Founder and managing director Chaled...
December 22, 2025

Okami Medical Announces $45 Million Financing and New CEO Appointment to Drive Next Phase of Growth

Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the successful close of an oversubscribed $45M financing led by new investor Gilde Healthcare with participation from existing investors including Vensana Capital and...
November 20, 2025